Tarsier Pharma's market-implied odds reflect the passage of its targeted July 2026 listing window without completion, as the clinical-stage ophthalmic biotech filed an F-1 in April and set terms for a $45-50 million raise at $8-10 per share in May, with an implied post-IPO valuation near $250-300 million. As a pre-revenue company developing TRS01 for ocular inflammation under an FDA special protocol assessment, execution risk remains elevated amid broader biotech sector volatility, limited institutional appetite for small IPOs, and no recent positive catalysts such as updated trial data or revised guidance. Trader consensus at 98.6% for no IPO before September 2026 incorporates these barriers while allowing for low-probability upside from rapid market stabilization or accelerated regulatory feedback that could reopen the window before month-end.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоНет IPO до сентября 2026 года 98.6%
$250M-$300M 2.9%
$400 млн – $450 млн 2.9%
$350M-$400M 1.9%
$15,112 Объем
$15,112 Объем
9 июл. 2026 г.
<250 млн долларов
2%
$250M-$300M
3%
$300M–$350M
<1%
$350M-$400M
2%
$400 млн – $450 млн
3%
>450 млн долларов
<1%
Нет IPO до сентября 2026 года
99%
Нет IPO до сентября 2026 года 98.6%
$250M-$300M 2.9%
$400 млн – $450 млн 2.9%
$350M-$400M 1.9%
$15,112 Объем
$15,112 Объем
9 июл. 2026 г.
<250 млн долларов
$907 Объем
2%
$250M-$300M
$979 Объем
3%
$300M–$350M
$561 Объем
<1%
$350M-$400M
$561 Объем
2%
$400 млн – $450 млн
$349 Объем
3%
>450 млн долларов
$680 Объем
<1%
Нет IPO до сентября 2026 года
$11,075 Объем
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's market-implied odds reflect the passage of its targeted July 2026 listing window without completion, as the clinical-stage ophthalmic biotech filed an F-1 in April and set terms for a $45-50 million raise at $8-10 per share in May, with an implied post-IPO valuation near $250-300 million. As a pre-revenue company developing TRS01 for ocular inflammation under an FDA special protocol assessment, execution risk remains elevated amid broader biotech sector volatility, limited institutional appetite for small IPOs, and no recent positive catalysts such as updated trial data or revised guidance. Trader consensus at 98.6% for no IPO before September 2026 incorporates these barriers while allowing for low-probability upside from rapid market stabilization or accelerated regulatory feedback that could reopen the window before month-end.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Открытие рынка: Jul 7, 2026, 9:12 AM ET
Объем
$15,112Дата окончания
9 июл. 2026 г.Открытие рынка
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's market-implied odds reflect the passage of its targeted July 2026 listing window without completion, as the clinical-stage ophthalmic biotech filed an F-1 in April and set terms for a $45-50 million raise at $8-10 per share in May, with an implied post-IPO valuation near $250-300 million. As a pre-revenue company developing TRS01 for ocular inflammation under an FDA special protocol assessment, execution risk remains elevated amid broader biotech sector volatility, limited institutional appetite for small IPOs, and no recent positive catalysts such as updated trial data or revised guidance. Trader consensus at 98.6% for no IPO before September 2026 incorporates these barriers while allowing for low-probability upside from rapid market stabilization or accelerated regulatory feedback that could reopen the window before month-end.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Объем
$15,112Дата окончания
9 июл. 2026 г.Открытие рынка
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's market-implied odds reflect the passage of its targeted July 2026 listing window without completion, as the clinical-stage ophthalmic biotech filed an F-1 in April and set terms for a $45-50 million raise at $8-10 per share in May, with an implied post-IPO valuation near $250-300 million. As a pre-revenue company developing TRS01 for ocular inflammation under an FDA special protocol assessment, execution risk remains elevated amid broader biotech sector volatility, limited institutional appetite for small IPOs, and no recent positive catalysts such as updated trial data or revised guidance. Trader consensus at 98.6% for no IPO before September 2026 incorporates these barriers while allowing for low-probability upside from rapid market stabilization or accelerated regulatory feedback that could reopen the window before month-end.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы